Latest Articles

  • Steroids in the acutely ill: Evolving recommendations and practice
    Stephen M. Pastores, MD, MACP, FCCP, FCCM
    Cleveland Clinic Journal of Medicine September 2022, 89 (9) 505-511; DOI: https://doi.org/10.3949/ccjm.89gr.22002

    New information has been generated with regard to what causes critical illness-related corticosteroid insufficiency, how to diagnose it, who should receive corticosteroid treatment, and what regimens to use.

  • Mucinous ascites: Pseudomyxoma peritonei
    Sansrita Nepal, MD, Adam Schwertner, MD and John M. Cunningham, MD
    Cleveland Clinic Journal of Medicine September 2022, 89 (9) 491-493; DOI: https://doi.org/10.3949/ccjm.89a.21086

    A 59-year-old man presented with progressive abdominal distention that limited daily activities and oral intake. The ascitic fluid was markedly viscous and jelly-like.

  • Cirrhotic coagulopathy: A rebalanced hemostasis
    Cirrhotic coagulopathy: A rebalanced hemostasis
    Achintya D. Singh, MD, MBBS, Simon R. Mucha, MD and Christina C. Lindenmeyer, MD
    Cleveland Clinic Journal of Medicine September 2022, 89 (9) 523-533; DOI: https://doi.org/10.3949/ccjm.89a.21018

    Cirrhosis affects all 3 phases of coagulation, leading to a delicate new equilibrium, easily disturbed and tipped toward either bleeding or thrombosis by acute events such as infection, renal failure, and invasive procedures.

  • Nasal herpes simplex virus infection
    Nina L. Tamashunas, MD, Robert Simonds, MD and Sarah Young, MD
    Cleveland Clinic Journal of Medicine September 2022, 89 (9) 495-496; DOI: https://doi.org/10.3949/ccjm.89a.21096

    Skin changes on the nose in a 37-year-old patient that began after a scratch were concerning for extensive nasal skin necrosis.

  • Widespread skin-thickening and hyperpigmentation
    India K. Poetzscher, Nikolai Klebanov, MD and Shinjita Das, MD, MPH
    Cleveland Clinic Journal of Medicine September 2022, 89 (9) 485-487; DOI: https://doi.org/10.3949/ccjm.89a.21099

    A 37-year-old military veteran presented with extensive velvety hyperpigmented plaques over nearly 15% of the total body surface.

  • Diversifying medical humanities: The case for Jay-Z
    Alok A. Khorana, MD
    Cleveland Clinic Journal of Medicine September 2022, 89 (9) 501-503; DOI: https://doi.org/10.3949/ccjm.89a.22011

    Physicians carry considerable power in the patient-physician relationship. Opening our minds to the viewpoints of others diffuses some of that power and grounds us in the communities we serve.

  • Xanthomas: Differentiating atherogenic from nonatherogenic
    Vy Mai, MD and Hossein Akhondi, MD
    Cleveland Clinic Journal of Medicine August 2022, 89 (8) 429-431; DOI: https://doi.org/10.3949/ccjm.89a.21088

    The patient had tendinous xanthomas on the dorsal joints of the hand and eruptive xanthomas on the buttock, as well as xanthoma striatum palmare on the volar aspect of the hand.

  • What are the considerations in patient selection and timing of risk-reducing mastectomy?
    Holly J. Pederson, MD, Allison W. Kurian, MD, MSc and Zahraa Al Hilli, MD
    Cleveland Clinic Journal of Medicine August 2022, 89 (8) 442-444; DOI: https://doi.org/10.3949/ccjm.89a.21114

    The option of risk-reducing mastectomy is for those at highest risk, and multidisciplinary conversations setting patient expectations are critical for optimal patient outcomes.

  • Do all patients with primary pulmonary coccidioidomycosis need antifungal therapy?
    Simran Gupta, MD, Nikita Ashcherkin, MD and Janis E. Blair, MD
    Cleveland Clinic Journal of Medicine August 2022, 89 (8) 451-455; DOI: https://doi.org/10.3949/ccjm.89a.21125

    Patients diagnosed with this condition who have no symptoms or are mildly symptomatic do not require treatment and can be closely monitored.

  • The role of GLP-1 receptor agonists in managing type 2 diabetes
    The role of GLP-1 receptor agonists in managing type 2 diabetes
    Noura Nachawi, MD, Pratibha PR Rao, MD, MPH and Vinni Makin, MBBS, MD, FACE
    Cleveland Clinic Journal of Medicine August 2022, 89 (8) 457-464; DOI: https://doi.org/10.3949/ccjm.89a.21110

    A review of the evidence regarding the benefits and adverse effects of GLP-1 receptor agonists in patients with type 2 diabetes mellitus or obesity.

Pages